U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H25N5O5
Molecular Weight 451.476
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXAZOSIN

SMILES

COc1cc2c(cc1OC)nc([nH]c2=N)N3CCN(CC3)C(=O)C4COc5ccccc5O4

InChI

InChIKey=RUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)

HIDE SMILES / InChI
may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

Originator

Curator's Comment:: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARDURA

Approved Use

INDICATIONS AND USAGE A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors.

Launch Date

657504000000
Primary
CARDURA

Approved Use

INDICATIONS AND USAGE A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors.

Launch Date

657504000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.7 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.6 ng/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14.3 ng/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
151.7 ng/mL
16 mg 1 times / day steady-state, oral
dose: 16 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
42.3 ng/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
65.5 ng/mL
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
162 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
268 ng × h/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.9 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15 h
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 h
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.6 h
16 mg 1 times / day steady-state, oral
dose: 16 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.8 h
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.3 h
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 19 years
Health Status: healthy
Age Group: 19 years
Sex: F
Sources:
Disc. AE: Sinus tachycardia...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia (1 patient)
Sources:
16 mg single, oral
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
DLT: Postural edema...
Dose limiting toxicities:
Postural edema (2.7%)
Sources:
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: unknown
Sources:
Disc. AE: Orthostatic dizziness...
AEs leading to
discontinuation/dose reduction:
Orthostatic dizziness (1 patient)
Sources:
16 mg 1 times / day steady, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
Health Status: unhealthy
Age Group: mean 59 years
Sex: M+F
Sources:
Disc. AE: Fatigue, Urinary incontinence...
Other AEs: Rhinitis...
AEs leading to
discontinuation/dose reduction:
Fatigue (3 patients)
Urinary incontinence (2 patients)
Other AEs:
Rhinitis (1 patient)
Sources:
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Nausea, Constipation...
Other AEs:
Nausea (below serious, 2 patients)
Constipation (below serious, 1 patient)
Allergy (below serious, 1 patient)
Dizziness (below serious, 1 patient)
Numbness (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinus tachycardia 1 patient
Disc. AE
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 19 years
Health Status: healthy
Age Group: 19 years
Sex: F
Sources:
Postural edema 2.7%
DLT
16 mg single, oral
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Orthostatic dizziness 1 patient
Disc. AE
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
healthy, adult
Health Status: healthy
Age Group: adult
Sex: unknown
Sources:
Rhinitis 1 patient
16 mg 1 times / day steady, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
Health Status: unhealthy
Age Group: mean 59 years
Sex: M+F
Sources:
Urinary incontinence 2 patients
Disc. AE
16 mg 1 times / day steady, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
Health Status: unhealthy
Age Group: mean 59 years
Sex: M+F
Sources:
Fatigue 3 patients
Disc. AE
16 mg 1 times / day steady, oral
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
Health Status: unhealthy
Age Group: mean 59 years
Sex: M+F
Sources:
Allergy below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Constipation below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Dizziness below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Numbness below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Nausea below serious, 2 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
2001
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
2001
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats.
2001
Is postural hypotension a real problem with antihypertensive medication?
2001
A comparison of selected antihypertensives and the use of conventional vs ambulatory blood pressure in the detection and treatment of hypertension.
2001
Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes.
2001 Dec
5alpha-reductase inhibitors: what role should they play?
2001 Dec
Terazosin, doxazosin, and prazosin: current clinical experience.
2001 Dec
Tamsulosin: current clinical experience.
2001 Dec
Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
2001 Dec
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
2001 Dec 18
Effects of antihypertensive agents on blood pressure during exercise.
2001 Nov
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial.
2001 Nov
Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery.
2001 Nov
Doxazosin and congestive heart failure.
2001 Nov 1
[Effect of doxazosin on postural changes in blood pressure using a multibiomedical recorder].
2001 Oct
Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure.
2001 Oct
A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease.
2001 Oct
Cardiovascular protection and blood pressure reduction: a meta-analysis.
2001 Oct 20
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
2001 Sep
The choice of antihypertensive drugs in patients with erectile dysfunction.
2002
Acute effects of serotonin on rat bladder contractility.
2002
[Doxazosin, of modified liberation, in hemodialyzed patients].
2002 Apr
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
2002 Apr
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
2002 Aug
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice.
2002 Aug
Medical therapy for benign prostatic hyperplasia progression.
2002 Aug
Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia.
2002 Aug
Critical evaluation of the problem of chronic urinary retention after orthotopic bladder substitution in women.
2002 Aug
alpha1-Adrenergic blockers in young men with primary bladder neck obstruction.
2002 Aug
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
2002 Aug 6
Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
2002 Aug-Sep
Double-blind, crossover, comparative study of doxazosin and enalapril in the treatment of hypertension in renal transplant patients under cyclosporine immunosuppression.
2002 Feb
Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy.
2002 Feb
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
2002 Feb
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
2002 Feb
Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.
2002 Feb 1
Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation.
2002 Jan
Relationship between arterial distensibility and low-frequency power spectrum of blood pressure in spontaneously hypertensive rats.
2002 Jan
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
2002 Jan 15
alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
2002 Jul
Managing benign prostatic hyperplasia.
2002 Jul 1
Successful blood pressure control in the African American Study of Kidney Disease and Hypertension.
2002 Jul 22
Doxazosin, an inferior antihypertensive agent?
2002 Jun
Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats: effect of the alpha1 -receptor blocker doxazosin.
2002 Mar
A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension.
2002 May
Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
2002 May-Jun
Doxazosin and congestive heart failure.
2002 May-Jun
Premature termination of clinical trials--lessons learned.
2002 May-Jun
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
2002 Sep 3
Patents

Patents

Sample Use Guides

Usual Adult Dose for Hypertension
Route of Administration: Oral
In Vitro Use Guide
Ring segments of splanchnic, peripheral, coronary, pulmonary and uterine conduit arteries obtained during surgery were studied in tissue baths. Resistance arteries dissected from various sites were studied in a myograph. Both conduit and resistance vessels contracted in response to the alpha 1-agonist phenylephrine (10(-7) to 10(-4) mol/l), an effect that was antagonized by the alpha 1-antagonist doxazosin (10(-8) to 10(-6) mol/l).
Name Type Language
DOXAZOSIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
DOXAZOSIN [MI]
Common Name English
C02CA04
Code English
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE
Systematic Name English
(+/-)-DOXAZOSIN
Common Name English
DOXAZOSIN [WHO-DD]
Common Name English
(4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHANONE
Systematic Name English
DOXAZOSIN [INN]
Common Name English
PIPERAZINE, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)CARBONYL)-
Systematic Name English
DOXAZOSIN [VANDF]
Common Name English
METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-
Systematic Name English
UK-33274
Code English
CARDURA XL
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175553
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
NDF-RT N0000000099
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
NCI_THESAURUS C29713
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
LIVERTOX 325
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
WHO-VATC QC02CA04
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
WHO-ATC C02CA04
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
Code System Code Type Description
WIKIPEDIA
DOXAZOSIN
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
RXCUI
49276
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY RxNorm
CAS
74191-85-8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
PUBCHEM
3157
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
LACTMED
Doxazosin
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
INN
5143
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
MERCK INDEX
M4752
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL707
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
IUPHAR
7170
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
DRUG CENTRAL
954
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
NCI_THESAURUS
C61737
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
EPA CompTox
74191-85-8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
MESH
D017292
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
FDA UNII
NW1291F1W8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
CAS
137888-77-8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
SUPERSEDED
EVMPD
SUB06384MIG
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
DRUG BANK
DB00590
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY